BWXT Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $902 million, up 18% year-over-year, with 9% organic growth.
Adjusted EBITDA: Increased 7% to $155 million, with a margin of 17.2%.
Adjusted Earnings Per Share (EPS): Rose 5% to $1.07.
Free Cash Flow: $115 million, leading to an increase in full-year guidance to $345 million - $360 million, up by $30 million.
Backlog: $8.4 billion, a 40% increase year-over-year, with a trailing 12-month book-to-bill ratio of 1.7x.

2. Strategic Updates and Business Highlights

Divestiture: Announced the sale of the medical business to Nordic Capital for up to $800 million, allowing BWXT to focus more on its core nuclear national security and commercial power sectors.
Acquisition: Completed the acquisition of Precision Components Group (PCG), enhancing capabilities in naval nuclear propulsion and commercial nuclear power.
Government Operations: Continued strong performance with a focus on naval propulsion and technical services, supported by a favorable 30-year shipbuilding plan from the Navy.
Commercial Operations: Revenue grew 72%, driven by strong demand in commercial nuclear power and nuclear medicine.
Advanced Nuclear: Achieved criticality with Antares's Mark-0 reactor, positioning BWXT as a leader in advanced nuclear fuels.

3. Forward Guidance and Outlook

Revenue Guidance: Raised to approximately $3.8 billion for 2026, indicating high teens growth compared to 2025.
Adjusted EBITDA Guidance: Increased by $10 million to a range of $662 million to $672 million.
Segment Expectations:
- Government Operations: High single-digit growth expected, revised from low teens.
- Commercial Operations: Revenue growth outlook increased to approximately 45%.
Adjusted EPS Guidance: Updated to $4.70 - $4.80, reflecting stronger operational performance.

4. Bad News, Challenges, or Points of Concern

Government Operations Margin: Adjusted EBITDA margin guidance for Government Operations was lowered to approximately 20.5% due to strong cost performance leading to lower reported revenue.
Investment Impact: Increased investments in U.S. capacity expansion may moderate near-term margin expansion in Commercial Operations.
Supply Chain and Labor: While supply chain management is currently stable, there are ongoing challenges in sourcing qualified labor, particularly for trades, which could impact future operational efficiency.

5. Notable Q&A Insights

Medical Business Sale: The decision to sell was strategic, allowing BWXT to focus on core areas, with retained minority interest in the medical business.
Nuclear Equipment Orders: BWXT is optimistic about securing at least one new nuclear equipment order by year-end, with ongoing discussions with major technology providers.
Project Janus: BWXT remains optimistic about the outcome of the Project Janus competition, with timing dependent on government decisions.
M&A Pipeline: BWXT is actively looking for M&A opportunities that align with its strategic focus on nuclear power and national security.
Capacity Expansion: Site selection for new commercial capacity is in progress, with a decision expected soon, reflecting strong demand in the nuclear sector.

Overall, BWXT reported a strong quarter with significant growth across its operations, strategic divestitures, and acquisitions positioning the company for future success, despite some challenges in labor and margin expectations.

BWXT — BWX Technologies, Inc.